Equities analysts expect Illumina, Inc. (NASDAQ:ILMN) to report earnings of $1.18 per share for the current quarter, according to Zacks. Seven analysts have made estimates for Illumina’s earnings. The lowest EPS estimate is $1.16 and the highest is $1.20. Illumina reported earnings of $0.85 per share in the same quarter last year, which indicates a positive year-over-year growth rate of 38.8%. The firm is scheduled to announce its next quarterly earnings results on Tuesday, January 30th.
On average, analysts expect that Illumina will report full year earnings of $3.75 per share for the current year, with EPS estimates ranging from $3.73 to $3.78. For the next year, analysts expect that the business will post earnings of $4.52 per share, with EPS estimates ranging from $4.20 to $4.82. Zacks’ EPS averages are an average based on a survey of sell-side analysts that that provide coverage for Illumina.
Illumina (NASDAQ:ILMN) last issued its earnings results on Tuesday, October 24th. The life sciences company reported $1.11 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.99 by $0.12. The company had revenue of $714.00 million for the quarter, compared to analyst estimates of $692.77 million. Illumina had a net margin of 30.34% and a return on equity of 19.42%. The company’s revenue for the quarter was up 17.6% on a year-over-year basis. During the same quarter last year, the firm earned $0.97 EPS.
Several research firms recently weighed in on ILMN. BidaskClub lowered shares of Illumina from a “buy” rating to a “hold” rating in a research note on Wednesday, December 6th. Zacks Investment Research raised shares of Illumina from a “hold” rating to a “buy” rating and set a $252.00 price objective on the stock in a research note on Tuesday, December 5th. Citigroup lifted their price objective on shares of Illumina from $180.00 to $220.00 and gave the stock a “neutral” rating in a research note on Wednesday, October 25th. Barclays lifted their price objective on shares of Illumina from $150.00 to $185.00 and gave the stock an “equal weight” rating in a research note on Wednesday, October 25th. Finally, Bank of America lifted their price objective on shares of Illumina from $215.00 to $240.00 and gave the stock a “buy” rating in a research note on Wednesday, October 25th. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and fourteen have issued a buy rating to the company’s stock. Illumina presently has a consensus rating of “Buy” and a consensus target price of $201.98.
Shares of Illumina (ILMN) traded down $1.47 during midday trading on Friday, hitting $212.64. 751,400 shares of the stock traded hands, compared to its average volume of 953,408. The company has a market cap of $31,260.06, a price-to-earnings ratio of 62.60, a PEG ratio of 3.54 and a beta of 0.79. The company has a quick ratio of 3.73, a current ratio of 4.22 and a debt-to-equity ratio of 0.41. Illumina has a one year low of $124.75 and a one year high of $230.72.
In other news, Director Jay T. Flatley sold 20,000 shares of Illumina stock in a transaction that occurred on Tuesday, September 26th. The shares were sold at an average price of $200.16, for a total value of $4,003,200.00. Following the sale, the director now directly owns 539,176 shares in the company, valued at $107,921,468.16. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Charles Dadswell sold 145 shares of Illumina stock in a transaction that occurred on Tuesday, October 3rd. The shares were sold at an average price of $202.23, for a total transaction of $29,323.35. The disclosure for this sale can be found here. Insiders have sold a total of 136,421 shares of company stock worth $28,489,101 over the last 90 days. Corporate insiders own 0.89% of the company’s stock.
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. raised its holdings in shares of Illumina by 2.6% in the second quarter. Vanguard Group Inc. now owns 9,904,340 shares of the life sciences company’s stock valued at $1,718,601,000 after purchasing an additional 255,498 shares during the last quarter. Ameriprise Financial Inc. increased its holdings in Illumina by 3.1% during the third quarter. Ameriprise Financial Inc. now owns 2,512,167 shares of the life sciences company’s stock worth $500,416,000 after buying an additional 76,452 shares during the last quarter. Capital World Investors increased its holdings in Illumina by 23.8% during the second quarter. Capital World Investors now owns 2,135,000 shares of the life sciences company’s stock worth $370,465,000 after buying an additional 410,000 shares during the last quarter. TIAA CREF Investment Management LLC increased its holdings in Illumina by 55.6% during the second quarter. TIAA CREF Investment Management LLC now owns 1,475,669 shares of the life sciences company’s stock worth $256,058,000 after buying an additional 527,548 shares during the last quarter. Finally, Winslow Capital Management LLC acquired a new position in Illumina during the second quarter worth $211,584,000. Institutional investors own 91.75% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This piece was first posted by The Lincolnian Online and is owned by of The Lincolnian Online. If you are accessing this piece on another domain, it was copied illegally and reposted in violation of US & international copyright laws. The correct version of this piece can be read at https://www.thelincolnianonline.com/2017/12/13/brokerages-anticipate-illumina-inc-ilmn-to-announce-1-18-earnings-per-share.html.
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.